Sanofi Eloxatin first-line approval
Executive Summary
Sanofi-Synthelabo's Eloxatin (oxaliplatin) approved Jan. 9 for first-line treatment of advanced colorectal cancer, in combination with 5-fluorouracil and leucovorin. Eloxatin was cleared August 2002 as second-line treatment in combination with 5-FU/leucovorin; Sanofi told investors in September that Eloxatin had captured 38% of the first-line market ahead of approval (1"The Pink Sheet" Sept. 8, 2003, p. 26)...
Sanofi-Synthelabo's Eloxatin (oxaliplatin) approved Jan. 9 for first-line treatment of advanced colorectal cancer, in combination with 5-fluorouracil and leucovorin. Eloxatin was cleared August 2002 as second-line treatment in combination with 5-FU/leucovorin; Sanofi told investors in September that Eloxatin had captured 38% of the first-line market ahead of approval (1 (Also see "Eloxatin Has 38% Share Of First-Line Colorectal Cancer Market, Sanofi Says" - Pink Sheet, 8 Sep, 2003.), p. 26).... |